In this study, researchers found that endoscopic therapy was the most effective strategy for patients with T1 CRC with less aggressive biomarker profiles and laparoscopic colectomy was the most effective for patients with more aggressive profiles.
Adults with advanced non-small cell lung cancer and impaired performance status experience significantly shorter survival after treatment with immune checkpoint inhibitors (ICIs) and receive ICIs more often than those with better performance status.
Breast cancer incidence in women aged 25 to 39 has been steadily increasing for the last 80 years, though researchers indicated that this increase cannot be attributed to changes in parity over time.
Though inflammatory bowel disease patients are generally at higher risk of HPV-related cancers, this data did not support intensified screening for vulvar or vaginal malignancies in female IBD patients.
The study also suggested that palliative care is rarely consulted for highly symptomatic patients with possibly curable cancer, highlighting the need for supportive care interventions.
A multi-institutional collaborative registry was created in order to quickly gather details from healthcare professionals related to cancer patients suspected or confirmed of having the novel coronavirus (COVID-19) resulting from infection with the SARS-CoV-2 virus.
These data suggest that clinicians should prescribe a short-term exercise program at the beginning of ADT to attenuate these important treatment-related side-effects.
This study suggested that PV prevalence among postmenopausal women may be high enough to warrant testing even in the absence of early diagnosis age or family history.
Copper intrauterine device users were found to have a lower risk of high-grade cervical neoplasms compared with levonorgestrel-releasing intrauterine system users.
Although the impact of COVID-19 on trials will vary based on many factors, the FDA outlined considerations to ensure the safety of trial participants, maintain compliance with good clinical practice, and minimize the risks to trial integrity.